A Phase 3 interventional study of Bexsero® and Routine vaccines in Meningococcal Disease and Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 2 sites in Taiwan. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-25.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 3, and was the 13th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 55 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is below the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
71 studies in Meningococcal Infections by GlaxoSmithKline: none open now, 1 under way, none of them phase 3. Of 70 finished, 60 (86%) have results posted.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 55th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2014, is one of 34 in phase 3, and was the 50th registered.
GlaxoSmithKline’s Meningococcal Infections studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 71 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Assess the safety and immunogenicity of a 3-dose schedule (at 2, 4, 6 months) of GSK Biologicals' Meningococcal B recombinant vaccine followed by a booster at 12 months when concomitantly administered with routine vaccines in healthy infants in Taiwan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
Biological: Bexsero®
Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
Biological: Routine vaccines
Four doses administered in the anterolateral area of the right or left thigh.
Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains
Percentage of subjects with hSBA titer ≥ 1:5 at 1 month following the third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).
Time frame: At Day 1 and at one month after the third vaccination (Day 152)
Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titer ≥ 1:4 Against Neisseria Meningitidis Serogroup B Strains
Percentage of subjects with hSBA titer ≥ 1:4 at 1 month after third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).
Time frame: At Day 1 and at one month after third vaccination (Day 152)
Percentage of Subjects With hSBA Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B, When Bexsero® Booster Was Given With Routine Vaccines (Priorix® + Varilrix® Vaccines)
Percentage of subjects with hSBA titer ≥ 1:5 before booster vaccination and after booster vaccination when Bexsero® booster dose was given with routine vaccines (Priorix® + Varilrix® vaccine) as compared to when only routine vaccines were administered.
Time frame: At Day 305 and Day 335
hSBA Geometric Mean Titers (GMTs) Against Neisseria Meningitidis Serogroup B Indicator Strains, When Bexsero® Vaccine Was Given With Routine Vaccines
hSBA GMTs against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 was evaluated at baseline (2 months of age, Day 1), 1 month after the third vaccination with Bexsero® with concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13®, Engerix®) (7 months of age, Day 152) or prior to the booster dose of Bexsero® with routine vaccines (Priorix®, Varilrix®) (12 months of age, Day 305) and 1 month after the booster dose (13 months of age, Day 335), as compared to when only routine vaccines were administered.
Time frame: At Day 1, Day 152, Day 305 and Day 335
hSBA Geometric Mean Ratios (GMRs) Against Neisseria Meningitidis Serogroup B Strains.
GMRs of post-vaccination versus pre-vaccination of hSBA titer against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 were evaluated at one month after the third vaccination with Bexsero® vaccine and concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13® and Engerix®) (Day 152) compared to baseline (Day 1) or at one month after the booster dose of Bexsero® vaccine with routine vaccines (Priorix®, Varilrix®) (Day 335) compared to prior to the booster dose (Day 305).
Time frame: At Day 1, Day 152, Day 305 and Day 335
Percentages of Subjects With hSBA Titers ≥1:8 Against Neisseria Meningitidis Serogroup B, When Bexsero® Vaccine Was Given With Routine Vaccines
Percentages of subjects with hSBA titers ≥1:8 against N.meningitidis serogroup B strains, at one month after concomitant administration of third primary dose of Bexsero® with routine vaccines \[Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®\] and at one month after concomitant administration of Bexsero® booster dose with routine vaccines \[Priorix® and Varilrix® vaccine\],as compared to when only routine vaccines were administered.
Time frame: At Day 1,Day 152,Day 305, Day 335
Number of Subjects Reporting Solicited Local Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.
Number of subjects reporting solicited local AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age)compared to when only routine vaccines were administered alone at 2,4,6 and 12 months. Solicited local symptoms assessed were Erythema, Induration, Swelling and Tenderness.
Time frame: From day 1 (6 hours) to day 7 after each vaccination (1st, 2nd, 3rd and 4th vaccination)
Number of Subjects Reporting Solicited Systemic Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.
Number of subjects reporting solicited systemic AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age) compared to when only routine vaccines were alone, at 2, 4, 6 and 12 months. Systemic solicited symptoms assessed were Change in Eating Habits, Diarrhea, Irritability, Persistent Crying, Rash, Sleepiness, Vomiting and Fever (body temperature ≥ 38.0 °C)
Time frame: From day 1 (6 hours) to day 7 after each vaccination
Number of Subjects Reporting Solicited Systemic AEs After Receiving Priorix® and Varilrix® Routine Vaccines (With and Without Bexsero® Vaccine) at 12 Months of Age.
Number of subjects who reported solicited systemic AEs reported after the administration of Varilrix® and Priorix® vaccines (with and without Bexsero® vaccine) at 12 months of age. Solicited systemic AEs assessed were Rash, Lymphadenopathy and Fever. This analysis was conducted for a prolonged period of 28 Days following Varilrix® and Priorix® administration.
Time frame: From Day 1 to Day 28 after vaccination
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination With Routine Vaccines
Number of subjects reporting any unsolicited AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B® or Priorix® and Varilrix®) compared to when only routine vaccines were administered alone.
Time frame: From day 1 to day 7 after each vaccination
Number of Subjects Reporting Serious Adverse Events (SAEs), Medically Attended AEs (MAEs) and AEs Leading to Premature Withdrawal and Death and AEs Leading to Hospitalization.
Number of subjects reporting SAEs, medically attended AEs and AEs leading to premature withdrawal from the study and leading to death and AEs leading to hospitalization following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix®) compared to when only routine vaccines were administered alone. SAEs assessed included medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Possibly or probably related SAE were SAEs assessed by the investigator as related to the vaccination. Medically attended AEs were events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason.
Time frame: Throughout the study period (Day 1 to Day 335)
Subjects were recruited from 2 sites in Taiwan
| Milestone | Bexsero + Routine Group | Routine Group |
|---|---|---|
| Started | 150 | 75 |
| Completed | 137 | 71 |
| Not completed | 13 | 4 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 4 |
Percentage of subjects with hSBA titer ≥ 1:5 at 1 month following the third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).
| Percentages of subjects | Bexsero + Routine Group | Routine Group |
|---|---|---|
| H44/76 strain [Day 1] | 0 (0.0 to 3.1) | 0 (0.0 to 6.1) |
| H44/76 strain [Day 152] | 100 (97.2 to 100) | 0 (0.0 to 5.4) |
| 5/99 strain [Day 1] | 1 (0.02 to 4.4) | 1 (0.04 to 7.8) |
| 5/99 strain [Day 152] | 100 (97.2 to 100) | 0 (0.0 to 5.1) |
| M10713 strain [Day 1] | 10 (4.9 to 17.6) | 19 (10 to 31.9) |
| M10713 strain [Day 152] | 59 (50.1 to 68.1) | 8 (2.5 to 17) |
| NZ98/254 strain [Day 1] | 0 (0.0 to 2.7) | 0 (0.0 to 5.1) |
| NZ98/254 strain [Day 152] | 79 (71.4 to 85.8) | 0 (0.0 to 5.1) |
Percentage of subjects with hSBA titer ≥ 1:4 at 1 month after third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).
| Percentage of subjects | Bexsero + Routine Group | Routine Group |
|---|---|---|
| H44/76 strain [Day 1] | 0 (0.0 to 3.1) | 0 (0.0 to 6.1) |
| H44/76 strain [Day 152] | 100 (97.2 to 100) | 0 (0.0 to 5.4) |
| 5/99 strain [Day 1] | 1 (0.02 to 4.4) | 1 (0.04 to 7.8) |
| 5/99 strain [Day 152] | 100 (97.2 to 100) | 0 (0.0 to 5.1) |
| M10713 strain [Day 1] | 11 (5.6 to 18.8) | 25 (14.1 to 37.8) |
| M10713 strain [Day 152] | 71 (61.9 to 78.6) | 8 (2.5 to 17.0) |
| NZ98/254 strain [Day 1] | 0 (0.0 to 2.7) | 0 (0.0 to 5.1) |
| NZ98/254 strain [Day 152] | 87 (80.6 to 92.5) | 0 (0.0 to 5.1) |
Percentage of subjects with hSBA titer ≥ 1:5 before booster vaccination and after booster vaccination when Bexsero® booster dose was given with routine vaccines (Priorix® + Varilrix® vaccine) as compared to when only routine vaccines were administered.
| Percentage of subjects | Bexsero + Routine Group | Routine Group |
|---|---|---|
| H44/76 strain [Day 305] | 81 (73.3 to 87.8) | 2 (0.04 to 8.4) |
| H44/76 strain [Day 335] | 99 (95.7 to 99.98) | 2 (0.04 to 8.4) |
| 5/99 strain [Day 305] | 99 (94.8 to 99.82) | 1 (0.04 to 7.7) |
| 5/99 strain [Day 335] | 99 (94.7 to 99.82) | 0 (0 to 5.1) |
| M10713 strain [Day 305] | 22 (14.8 to 29.6) | 11 (4.4 to 20.9) |
| M10713 strain [Day 335] | 92 (86.3 to 96.2) | 13 (6.1 to 23.3) |
| NZ98/254 strain [Day 305] | 17 (11 to 24.3) | 1 (0.04 to 7.7) |
| NZ98/254 strain [Day 335] | 94 (88.7 to 97.4) | 0 (0 to 5.1) |
hSBA GMTs against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 was evaluated at baseline (2 months of age, Day 1), 1 month after the third vaccination with Bexsero® with concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13®, Engerix®) (7 months of age, Day 152) or prior to the booster dose of Bexsero® with routine vaccines (Priorix®, Varilrix®) (12 months of age, Day 305) and 1 month after the booster dose (13 months of age, Day 335), as compared to when only routine vaccines were administered.
| Titer | Bexsero + Routine Group | Routine Group |
|---|---|---|
| H44/76 strain [Day 1] | 1.01 (0.99 to 1.02) | 1.02 (0.98 to 1.05) |
| H44/76 strain [Day 152] | 72 (64 to 81) | 1.01 (0.99 to 1.03) |
| H44/76 strain [Day 305] | 11 (9.27 to 13) | 1.26 (1.06 to 1.5) |
| H44/76 strain [Day 335] | 157 (131 to 188) | 1.1 (1.01 to 1.19) |
| 5/99 strain [Day 1] | 1.08 (0.98 to 1.18) | 1.03 (0.98 to 1.08) |
| 5/99 strain [Day 152] | 963 (864 to 1073) | 1 (1 to 1) |
| 5/99 strain [Day 305] | 205 (174 to 242) | 1.1 (0.91 to 1.33) |
| 5/99 strain [Day 335] | 2315 (1893 to 2832) | 1 (1 to 1) |
| M10713 strain [Day 1] | 1.36 (1.2 to 1.54) | 1.75 (1.37 to 2.24) |
| M10713 strain [Day 152] | 8.41 (6.63 to 11) | 1.25 (1.08 to 1.46) |
| M10713 strain [Day 305] | 2.18 (1.81 to 2.63) | 1.6 (1.34 to 1.91) |
| M10713 strain [Day 335] | 17 (14 to 20) | 1.58 (1.33 to 1.89) |
| NZ98/254 strain [Day 1] | 1.01 (0.99 to 1.02) | 1 (1 to 1) |
| NZ98/254 strain [Day 152] | 9.2 (7.82 to 11) | 1.02 (0.98 to 1.05) |
| NZ98/254 strain [Day 305] | 1.91 (1.63 to 2.25) | 1.04 (0.98 to 1.1) |
| NZ98/254 strain [Day 335] | 26 (21 to 31) | 1 (1 to 1) |
GMRs of post-vaccination versus pre-vaccination of hSBA titer against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 were evaluated at one month after the third vaccination with Bexsero® vaccine and concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13® and Engerix®) (Day 152) compared to baseline (Day 1) or at one month after the booster dose of Bexsero® vaccine with routine vaccines (Priorix®, Varilrix®) (Day 335) compared to prior to the booster dose (Day 305).
| Ratio | Bexsero + Routine Group | Routine Group |
|---|---|---|
| H44/76 strain [Day 152/Day 1] | 71 (63 to 80) | 0.99 (0.95 to 1.04) |
| H44/76 strain [Day 335/Day 305] | 155 (127 to 188) | 1.07 (0.97 to 1.19) |
| 5/99 strain [Day 152/Day 1] | 875 (752 to 1019) | 0.97 (0.93 to 1.03) |
| 5/99 strain [Day 335/Day 305] | 2110 (1674 to 2659) | 0.97 (0.93 to 1.03) |
| M10713 strain [Day 152/Day 1] | 5.69 (4.25 to 7.61) | 0.68 (0.54 to 0.85) |
| M10713 strain [Day 335/Day 305] | 12 (8.99 to 15) | 0.91 (0.68 to 1.21) |
| NZ98/254 strain [Day 152/Day 1] | 9.18 (7.79 to 11) | 1.02 (0.98 to 1.05) |
| NZ98/254 strain [Day 335/Day 305] | 25 (21 to 31) | 1 (1 to 1) |
Percentages of subjects with hSBA titers ≥1:8 against N.meningitidis serogroup B strains, at one month after concomitant administration of third primary dose of Bexsero® with routine vaccines \[Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®\] and at one month after concomitant administration of Bexsero® booster dose with routine vaccines \[Priorix® and Varilrix® vaccine\],as compared to when only routine vaccines were administered.
| Percentages of subjects | Bexsero + Routine Group | Routine Group |
|---|---|---|
| H44/76 strain (Day 1) | 0 (0.0 to 2.8) | 0 (0.0 to 5.5) |
| H44/76 strain (Day 152) | 100 (97.2 to 100) | 0 (0.0 to 5.4) |
| H44/76 strain (Day 305) | 66 (56.8 to 74.2) | 2 (0.04 to 8.4) |
| H44/76 strain (Day 335) | 99 (95.7 to 99.98) | 0 (0.0 to 5.6) |
| 5/99 strain (Day 1) | 1 (0.02 to 3.9) | 0 (0.0 to 5.0) |
| 5/99 strain (Day 152) | 100 (97.2 to 100) | 0 (0.0 to 5.1) |
| 5/99 strain (Day 305) | 99 (94.8 to 99.82) | 1 (0.04 to 7.7) |
| 5/99 strain (Day 335) | 99 (94.7 to 99.82) | 0 (0.0 to 5.1) |
| M10713 strain (Day 1) | 3 (0.9 to 8.2) | 8 (2.6 to 17.3) |
| M10713 strain (Day 152) | 49 (39.7 to 58.0) | 5 (1.0 to 12.9) |
| M10713 strain (Day 305) | 15 (9.7 to 22.8) | 3 (0.37 to 10.7) |
| M10713 strain (Day 335) | 77 (68.7 to 83.9) | 6 (1.6 to 14.2) |
| NZ98/254 strain (Day 1) | 0 (0.0 to 2.5) | 0 (0.0 to 4.9) |
| NZ98/254 strain (Day 152) | 59 (49.7 to 66.9) | 0 (0.0 to 5.1) |
| NZ98/254 strain (Day 305) | 9 (4.6 to 14.9) | 0 (0.0 to 5.1) |
| NZ98/254 strain (Day 335) | 86 (79.0 to 91.4) | 0 (0.0 to 5.1) |
Number of subjects reporting solicited local AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age)compared to when only routine vaccines were administered alone at 2,4,6 and 12 months. Solicited local symptoms assessed were Erythema, Induration, Swelling and Tenderness.
| Number of participants | Bexsero + Routine Group | Routine Group |
|---|---|---|
| Any Erythema (1st Bexsero®) | 54 | — |
| Grade 3 Erythema (1st Bexsero®) | 0 | — |
| Any Swelling (1st Bexsero®) | 34 | — |
| Grade 3 Swelling (1st Bexsero®) | 0 | — |
| Any Induration (1st Bexsero®) | 63 | — |
| Grade 3 Induration (1st Bexsero®) | 0 | — |
| Any Tenderness (1st Bexsero®) | 75 | — |
| Grade 3 Tenderness (1st Bexsero®) | 8 | — |
| Any Erythema (1st Infanrix-IPV + Hib®) | 26 | 3 |
| Grade 3 Erythema(1st Infanrix-IPV+Hib®) | 0 | 0 |
| Any Swelling (1st Infanrix-IPV + Hib®) | 15 | 3 |
| Grade 3 Swelling(1st Infanrix-IPV+Hib®) | 0 | 0 |
| Any Tenderness (1st Infanrix-IPV + Hib®) | 45 | 12 |
| Grade 3Tenderness(1st Infanrix-IPV+Hib®) | 2 | 0 |
| Any Induration(1st Infanrix-IPV + Hib®) | 23 | 11 |
| Grade 3Induration(1st Infanrix-IPV+Hib®) | 0 | 0 |
| Any Erythema (1st Prevenar-13®) | 26 | 9 |
| Grade 3 Erythema (1st Prevenar-13®) | 0 | 0 |
| Any Induration (1st Prevenar-13®) | 29 | 15 |
| Grade 3 Induration (1st Prevenar-13®) | 0 | 0 |
| Any Swelling (1st Prevenar-13®) | 11 | 4 |
| Grade 3 Swelling (1st Prevenar-13®) | 0 | 0 |
| Any Tenderness (1st Prevenar-13®) | 50 | 12 |
| Grade 3 Tenderness (1st Prevenar-13®) | 3 | 0 |
| Any Erythema (2nd Bexsero®) | 59 | — |
| Grade 3 Erythema (2nd Bexsero®) | 0 | — |
| Any Swelling (2nd Bexsero®) | 35 | — |
| Grade 3 Swelling (2nd Bexsero®) | 0 | — |
| Any Induration (2nd Bexsero®) | 51 | — |
| Grade 3 Induration (2nd Bexsero®) | 0 | — |
| Any Tenderness (2nd Bexsero®) | 67 | — |
| Grade 3 Tenderness (2nd Bexsero®) | 5 | — |
| Any Erythema (2nd Infanrix-IPV + Hib®) | 39 | 12 |
| Grade 3 Erythema(2nd Infanrix-IPV+Hib®) | 0 | 0 |
| Any Swelling (2nd Infanrix-IPV + Hib®) | 18 | 6 |
| Grade 3 Swelling(2nd Infanrix-IPV+Hib®) | 0 | 0 |
| Any Induration (2nd Infanrix-IPV + Hib®) | 23 | 16 |
| Grade 3Induration(2nd Infanrix-IPV+Hib®) | 0 | 0 |
| Any Tenderness (2nd Infanrix-IPV + Hib®) | 45 | 10 |
| Grade 3Tenderness(2nd Infanrix-IPV+Hib®) | 3 | 0 |
| Any Erythema (2nd Prevenar-13®) | 35 | 12 |
| Grade 3 Erythema (2nd Prevenar-13®) | 0 | 0 |
| Any Induration (2nd Prevenar-13®) | 18 | 8 |
| Grade 3 Induration (2nd Prevenar-13®) | 0 | 0 |
| Any Swelling (2nd Prevenar-13®) | 12 | 6 |
| Grade 3 Swelling (2nd Prevenar-13®) | 0 | 0 |
| Any Tenderness (2nd Prevenar-13®) | 44 | 9 |
| Grade 3 Tenderness (2nd Prevenar-13®) | 3 | 0 |
| Any Erythema (3rd Engerix-B®) | 33 | 12 |
| Grade 3 Erythema (3rd Engerix-B®) | 0 | 0 |
| Any Induration (3rd Engerix-B®) | 33 | 17 |
| Grade 3 Induration (3rd Engerix-B®) | 0 | 0 |
| Any Swelling (3rd Engerix-B®) | 25 | 6 |
| Grade 3 Swelling (3rd Engerix-B®) | 0 | 0 |
| Any Tenderness (3rd Engerix-B®) | 45 | 7 |
| Grade 3 Tenderness (3rd Engerix-B®) | 3 | 0 |
| Any Erythema (3rd Bexsero®) | 55 | — |
| Grade 3 Erythema (3rd Bexsero®) | 0 | — |
| Any Induration (3rd Bexsero®) | 57 | — |
| Grade 3 Induration (3rd Bexsero®) | 0 | — |
| Any Swelling (3rd Bexsero®) | 49 | — |
| Grade 3 Swelling (3rd Bexsero®) | 0 | — |
| Any Tenderness (3rd Bexsero®) | 68 | — |
| Grade 3 Tenderness (3rd Bexsero®) | 6 | — |
| Any Swelling (3rd Infanrix-IPV+Hib®) | 20 | 10 |
| Grade 3 Swelling (3rd Infanrix-IPV+Hib®) | 0 | 0 |
| Any Erythema (3rd Infanrix-IPV+Hib®) | 28 | 15 |
| Grade 3 Erythema (3rd Infanrix-IPV+Hib®) | 0 | 0 |
| Any Induration(3rd Infanrix-IPV+Hib®) | 25 | 16 |
| Grade 3Induration(3rd Infanrix-IPV+Hib®) | 0 | 0 |
| Any Tenderness (3rd Infanrix-IPV+ Hib®) | 42 | 8 |
| Grade 3Tenderness(3rd Infanrix-IPV+Hib®) | 2 | 0 |
| Any Erythema (3rd Prevenar-13®) | 27 | 12 |
| Grade 3 Erythema (3rd Prevenar-13®) | 0 | 0 |
| Any Induration (3rd Prevenar-13®) | 21 | 11 |
| Grade 3 Induration (3rd Prevenar-13®) | 0 | 0 |
| Any Swelling (3rd Prevenar-13®) | 17 | 4 |
| Grade 3 Swelling (3rd Prevenar-13®) | 0 | 0 |
| Any Tenderness (3rd Prevenar-13®) | 45 | 9 |
| Grade 3 Tenderness (3rd Prevenar-13®) | 3 | 0 |
| Any Erythema (4th Bexsero®) | 53 | — |
| Grade 3 Erythema (4th Bexsero®) | 0 | — |
| Any Swelling (4th Bexsero®) | 44 | — |
| Grade 3 Swelling (4th Bexsero®) | 0 | — |
| Any Induration (4th Bexsero®) | 56 | — |
| Grade 3 Induration(4th Bexsero®) | 0 | — |
| Any Tenderness (4th Bexsero®) | 66 | — |
| Grade 3 Tenderness (4th Bexsero®) | 6 | — |
| Any Erythema (4th Priorix®) | 24 | 13 |
| Grade 3 Erythema (4th Priorix®) | 0 | 0 |
| Any Induration (4th Priorix®) | 15 | 6 |
| Grade 3 Induration (4th Priorix®) | 0 | 0 |
| Any Swelling (4th Priorix®) | 19 | 4 |
| Grade 3 Swelling (4th Priorix®) | 0 | 0 |
| Any Tenderness (4th Priorix®) | 37 | 6 |
| Grade 3 Tenderness (4th Priorix®) | 3 | 0 |
| Any Erythema (4th Varilrix®) | 32 | 14 |
| Grade 3 Erythema (4th Varilrix®) | 0 | 0 |
| Any Induration (4th Varilrix®) | 14 | 7 |
| Grade 3 Induration (4th Varilrix®) | 0 | 0 |
| Any Swelling (4th Varilrix®) | 21 | 6 |
| Grade 3 Swelling (4th Varilrix®) | 0 | 0 |
| Any Tenderness (4th Varilrix®) | 41 | 5 |
| Grade 3 Tenderness (4th Varilrix®) | 3 | 0 |
Number of subjects reporting solicited systemic AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age) compared to when only routine vaccines were alone, at 2, 4, 6 and 12 months. Systemic solicited symptoms assessed were Change in Eating Habits, Diarrhea, Irritability, Persistent Crying, Rash, Sleepiness, Vomiting and Fever (body temperature ≥ 38.0 °C)
| Number of participants | Bexsero + Routine Group | Routine Group |
|---|---|---|
| Any Change in Eating Habits (1st vacc) | 92 | 26 |
| Grade3 Change in Eating Habits(1st vacc) | 0 | 0 |
| Any Change in Eating Habits (2nd vacc) | 72 | 21 |
| Grade3 Change in Eating Habits(2nd vacc) | 2 | 0 |
| Any Change in Eating Habits (3rd vacc) | 72 | 17 |
| Grade3 Change in Eating Habits(3rd vacc) | 1 | 0 |
| Any Diarrhea (1st vacc) | 28 | 8 |
| Grade 3 Diarrhea (1st vacc) | 2 | 1 |
| Any Diarrhea (2nd vacc) | 30 | 9 |
| Grade 3 Diarrhea (2nd vacc) | 1 | 0 |
| Any Diarrhea (3rd vacc) | 19 | 4 |
| Grade 3 Diarrhea (3rd vacc) | 0 | 0 |
| Any Irritability (1st vacc) | 111 | 32 |
| Grade 3 Irritability (1st vacc) | 3 | 0 |
| Any Irritability (2nd vacc) | 90 | 31 |
| Grade 3 Irritability (2nd vacc) | 5 | 0 |
| Any Irritability (3rd vacc) | 94 | 28 |
| Grade 3 Irritability (3rd vacc) | 3 | 1 |
| Any Persistent Crying (1st vacc) | 96 | 30 |
| Grade 3 Persistent Crying (1st vacc) | 5 | 0 |
| Any Persistent Crying (2nd vacc) | 82 | 23 |
| Grade 3 Persistent Crying (2nd vacc) | 5 | 0 |
| Any Persistent Crying (3rd vacc) | 72 | 28 |
| Grade 3 Persistent Crying (3rd vacc) | 3 | 0 |
| Any Rash (1st vacc) | 18 | 4 |
| Grade 3 Rash (1st vacc) | 0 | 0 |
| Any Rash (2nd vacc) | 18 | 8 |
| Grade 3 Rash (2nd vacc) | 0 | 1 |
| Any Rash (3rd vacc) | 16 | 4 |
| Grade 3 Rash (3rd vacc) | 1 | 0 |
| Any Sleepiness (1st vacc) | 79 | 33 |
| Grade 3 Sleepiness (1st vacc) | 0 | 1 |
| Any Sleepiness (2nd vacc) | 66 | 21 |
| Grade 3 Sleepiness (2nd vacc) | 0 | 0 |
| Any Sleepiness (3rd vacc) | 49 | 13 |
| Grade 3 Sleepiness (3rd vacc) | 0 | 0 |
| Any Vomiting (1st vacc) | 21 | 6 |
| Grade 3 Vomiting (1st vacc) | 0 | 0 |
| Any Vomiting (2nd vacc) | 16 | 9 |
| Grade 3 Vomiting (2nd vacc) | 0 | 0 |
| Any Vomiting (3rd vacc) | 15 | 7 |
| Grade 3 Vomiting (3rd vacc) | 0 | 0 |
| Fever (1st vacc) | 71 | 11 |
| Fever (2nd vacc) | 72 | 11 |
| Fever (3rd vacc) | 68 | 12 |
| Any Change in Eating Habits (4th vacc) | 58 | 19 |
| Grade3 Change in Eating Habits(4th vacc) | 2 | 1 |
| Any Diarrhea (4th vacc) | 27 | 10 |
| Grade 3 Diarrhea (4th vacc) | 1 | 0 |
| Any Irritability (4th vacc) | 71 | 16 |
| Grade 3 Irritability (4th vacc) | 2 | 0 |
| Any Persistent Crying (4th vacc) | 58 | 15 |
| Grade 3 Persistent Crying (4th vacc) | 0 | 1 |
| Any Rash (4th vacc) | 25 | 9 |
| Grade 3 Rash (4th vacc) | 1 | 0 |
| Any Sleepiness (4th vacc) | 36 | 9 |
| Grade 3 Sleepiness (4th vacc) | 0 | 0 |
| Any Vomiting (4th vacc) | 10 | 6 |
| Grade 3 Vomiting (4th vacc) | 0 | 0 |
| Fever (4th vacc) | 60 | 6 |
| Lymphadenopathy (4th vacc) | 1 | 1 |
Number of subjects who reported solicited systemic AEs reported after the administration of Varilrix® and Priorix® vaccines (with and without Bexsero® vaccine) at 12 months of age. Solicited systemic AEs assessed were Rash, Lymphadenopathy and Fever. This analysis was conducted for a prolonged period of 28 Days following Varilrix® and Priorix® administration.
| Number of participants | Bexsero + Routine Group | Routine Group |
|---|---|---|
| Any Rash (4th vacc) | 50 | 24 |
| Grade 3 rash (4th vacc) | 5 | 5 |
| Lymphadenopathy (4th vacc) | 34 | 21 |
| Fever (temperature ≥ 38.0°C) | 91 | 33 |
| Grade 3 fever (temperature ≥ 40.0°C) | 2 | 5 |
Number of subjects reporting any unsolicited AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B® or Priorix® and Varilrix®) compared to when only routine vaccines were administered alone.
| Number of subjects | Bexsero + Routine Group | Routine Group |
|---|---|---|
| Any AEs (1st vacc) | 46 | 8 |
| At least possible related AEs (1st vacc) | 35 | 6 |
| Any AEs (2nd vacc) | 30 | 7 |
| At least possible related AEs (2nd vacc) | 22 | 5 |
| Any AEs (3rd vacc) | 51 | 18 |
| At least possible related AEs (3rd vacc) | 45 | 7 |
| Any AEs (booster) | 43 | 9 |
| At least possible related AEs (booster) | 37 | 4 |
Number of subjects reporting SAEs, medically attended AEs and AEs leading to premature withdrawal from the study and leading to death and AEs leading to hospitalization following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix®) compared to when only routine vaccines were administered alone. SAEs assessed included medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Possibly or probably related SAE were SAEs assessed by the investigator as related to the vaccination. Medically attended AEs were events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason.
| Number of participants | Bexsero + Routine Group | Routine Group |
|---|---|---|
| Any SAEs | 13 | 8 |
| At least possible related SAEs | 0 | 0 |
| AEs resulting in premature withdrawal | 4 | 0 |
| AEs leading to hospitalization | 13 | 8 |
| Medically attended AEs | 131 | 66 |
| AEs leading to death | 0 | 0 |
Collected over Solicited local AEs and systemic symptoms: from Day 1 to Day 7 after each vaccination; Unsolicited AEs and SAEs: throughout the study period (from Day 1 to Day 335).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bexsero + Routine Group | 0/148 (0%) | 13/145 (9%) | 148/148 (100%) |
| Routine Group | 0/73 (0%) | 8/72 (11.1%) | 72/73 (98.6%) |
| Event | Bexsero + Routine Group | Routine Group |
|---|---|---|
| Urinary tract infectionInfections and infestations | 4/145 | 0/72 |
| BronchiolitisInfections and infestations | 3/145 | 1/72 |
| Kawasaki's diseaseVascular disorders | 0/145 | 1/72 |
| SeizureNervous system disorders | 0/145 | 1/72 |
| PyrexiaGeneral disorders | 1/145 | 1/72 |
| ColitisGastrointestinal disorders | 0/145 | 1/72 |
| RashSkin and subcutaneous tissue disorders | 0/145 | 1/72 |
| GastroenteritisInfections and infestations | 1/145 | 1/72 |
| Otitis media acuteInfections and infestations | 1/145 | 1/72 |
| PneumoniaInfections and infestations | 1/145 | 1/72 |
| Event | Bexsero + Routine Group | Routine Group |
|---|---|---|
| PyrexiaGeneral disorders | 134/148 | 51/73 |
| IrritabilityPsychiatric disorders | 127/148 | 50/73 |
| Eating disorderPsychiatric disorders | 125/148 | 43/73 |
| CryingGeneral disorders | 124/148 | 50/73 |
| Injection site painGeneral disorders | 121/148 | 27/73 |
| Injection site erythemaGeneral disorders | 113/148 | 35/73 |
| SomnolenceNervous system disorders | 111/148 | 45/73 |
| Injection site indurationGeneral disorders | 105/148 | 39/73 |
| NasopharyngitisInfections and infestations | 86/148 | 45/73 |
| Injection site swellingGeneral disorders | 89/148 | 24/73 |
| Age, Continuous(Days) | Bexsero + Routine Group | Routine Group | Total |
|---|---|---|---|
| Mean | 67.9 ± 6.46 | 68.9 ± 6.86 | 68.3 ± 6.60 |
| Sex: Female, Male(Participants) | Bexsero + Routine Group | Routine Group | Total |
|---|---|---|---|
| Female | 82 | 27 | 109 |
| Male | 68 | 48 | 116 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Sep 2014 to primary completion in Dec 2015, 15 months.
Results were first posted in Jun 2018, 2 years 5 months after primary completion. A results delay was requested in Jan 2016.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 15 months is close to that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine